Khosla Ventures, a venture capital firm, led a $43m Series B round iin Bionaut Labs, a company that uses microscale robots to revolutionize the treatment of central nervous system diseases, with participation from Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace, Gaingels, Upfront Ventures, BOLD Capital Partners, Revolution VC, and Compound. “There has been a dearth of innovation around treatments for conditions that cause tremendous suffering, in large part because past failures have discouraged even the best of researchers. Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough,” Michael Shpigelmacher, Bionaut Labs Co-Founder and CEO.